Date: 2011-03-14
Type of information: Fundraising
Company: Activiomics (UK)
Investors: IP Group (UK) - IP Venture Fund, (a venture capital fund managed by IP Group) - members of Activiomics' management
Amount: £500,000 (€578 000)
Funding type: funding round
Planned used: The funds raised will strengthen Activiomics\' ability to grow its partnerships with pharmaceutical and biotechnology companies and to pursue the identification of novel predictive and prognostic markers in oncology using its proprietary label-free technology on exclusively accessed human tissue samples. The company will have access to state of the art mass spectrometry facilities while being advised by world class scientists, including its scientific founders: world leading expert in PI3K signalling Bart Vanhaesebroeck and pioneer in the field of label free proteomics Pedro Cutillas.
Others: Activiomics, a developer of technologies for the identification and the development of drug biomarkers, diagnostics and drug candidates, has received investment of over £500,000 led by IP Group plc, the developer of intellectual property based businesses. Activiomics\' proprietary technology has broad application in the area of biomarker and drug discovery in a number of disease areas, including oncology and inflammation. Since its incorporation in February 2010, the company has demonstrated the value of its technology through revenue generating partnerships with big pharma, including GSK, UCB and Genentech.
Activiomics\' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of phosphorylation sites. Phosphorylation is critical mediator all cellular processes and hence sites of phosphorylation represent an important class of novel biomarkers. Activiomics\' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics. Activiomics commercialises its technology by partnering directly with pharmaceutical and biotechnology companies on bespoke programmes of work. In addition it is using its TIQUAS technology in combination with exclusively accessed primary breast and kidney cancer samples to generate proof of concept data and high value data packages for novel predictive and prognostic markers programmes.
Therapeutic area: Cancer - Oncology - Technology - Services
